Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

INVO Fertility (IVF) Income from Continuing Operations (2016 - 2025)

INVO Fertility has reported Income from Continuing Operations over the past 15 years, most recently at 2644625.0 for Q3 2025.

  • Quarterly Income from Continuing Operations fell 62.18% to 2644625.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 26880798.0 through Sep 2025, down 259.95% year-over-year, with the annual reading at 9095838.0 for FY2024, 13.2% down from the prior year.
  • Income from Continuing Operations was 2644625.0 for Q3 2025 at INVO Fertility, up from 3209094.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 101782.0 in Q4 2021 and troughed at 17403586.0 in Q1 2025.
  • The 5-year median for Income from Continuing Operations is 2481326.0 (2021), against an average of 3045218.89.
  • Year-over-year, Income from Continuing Operations soared 102.67% in 2021 and then tumbled 2818.59% in 2022.
  • A 5-year view of Income from Continuing Operations shows it stood at 101782.0 in 2021, then tumbled by 2818.59% to 2767035.0 in 2022, then grew by 27.88% to 1995642.0 in 2023, then crashed by 81.57% to 3623493.0 in 2024, then rose by 27.01% to 2644625.0 in 2025.
  • Per Business Quant, the three most recent readings for IVF's Income from Continuing Operations are 2644625.0 (Q3 2025), 3209094.0 (Q2 2025), and 17403586.0 (Q1 2025).